These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35869779)

  • 21. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
    Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an
    Bian X; Liu X; Chen Y; Chen D; Li J; Zhang J
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?
    De Cock PA; Desmet S; De Jaeger A; Biarent D; Dhont E; Herck I; Vens D; Colman S; Stove V; Commeyne S; Vande Walle J; De Paepe P
    J Antimicrob Chemother; 2017 Mar; 72(3):801-804. PubMed ID: 27999035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Rolsma S; Patel PC; Watanabe A; Fishbane N; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0131222. PubMed ID: 36622154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function.
    Gijsen M; Elkayal O; Annaert P; Van Daele R; Meersseman P; Debaveye Y; Wauters J; Dreesen E; Spriet I
    Infect Drug Resist; 2022; 15():53-62. PubMed ID: 35035223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
    Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis.
    Wang ZM; Chen XY; Bi J; Wang MY; Xu BP; Tang BH; Li C; Zhao W; Shen AD
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
    Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL
    J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with meropenem pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion.
    Tournayre S; Mathieu O; Villiet M; Besnard N; Brunot V; Daubin D; Platon L; Corne P; Klouche K; Larcher R
    Int J Antimicrob Agents; 2023 Aug; 62(2):106868. PubMed ID: 37244425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill Patients.
    Paal M; Heilmann M; Koch S; Bertsch T; Steinmann J; Höhl R; Liebchen U; Schuster C; Kleine FM; Vogeser M
    Clin Lab; 2019 Sep; 65(9):. PubMed ID: 31532096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.
    Gijsen M; Dreesen E; Van Daele R; Annaert P; Debaveye Y; Wauters J; Spriet I
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34064676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
    Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
    Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients.
    Liebchen U; Weinelt F; Scharf C; Schroeder I; Paal M; Zoller M; Kloft C; Jung J; Michelet R
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0183121. PubMed ID: 34871092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meropenem serum concentrations in intensive care patients: a retrospective analysis.
    Uricová J; Kacířová I; Brozmanová H
    Ceska Slov Farm; 2020; 69(5-6):230-236. PubMed ID: 33736449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.